Salute e Benessere

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025

AggregatedpresentationbydayandbymarketStatement of transactions in own shares from July 7th to July 11th 2025 Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marché IPSEN549300M6SGDPB4Z94P1107/07/2025FR00102591501047102,4581662CCXE...
Nasdaq GlobeNewswire
16/07/2025

Virbac: in the first half of 2025, revenue recorded solid growth of +5.6% at…

KEY FIGURESRevenue in first half of 2025 €738.3MGrowth at constant exchange ratesand scope 1 +5.6includingcompanion animals +7.1%farm animals +5.1%Growth at constantexchange rates 2 +7.8% Overallchange +5.0% Quarterly consolidated revenue Our second-quarter revenue reached €363.1 million, marking a +6.4% increase at constant exchange rates and scope compared to the same period...
Nasdaq GlobeNewswire
16/07/2025

Hemostats Market worth $4.00 billion by 2030 with 6.4% CAGR | MarketsandMarkets™

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9571619 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9571619 Browse in-depth TOC on "Hemostats Market" 186 - Tables 43 - Figures 215 - Pages By type,the hemostats market is segmented into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats...
PR Newswire
16/07/2025

CARESYNTAX ELEVATES MATT KRUEGER TO CHIEF EXECUTIVE OFFICER

"Matt has played a central role in building Caresyntax over the past decade," said Kogan and von Siemens. "His leadership has driven our global expansion, deepened strategic partnerships, and helped shape the business into what it is today. We're confident Matt is the right leader for this next phase. His deep knowledge of our customers and ability to scale complex organizations will be essential as Caresyntax advances its mission to make surgery safer, smarter, and more…
PR Newswire
16/07/2025

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat…

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.A statistically significant reduction in mean pain scores was observed from Visit 1 to the end of treatment Visit...
Nasdaq GlobeNewswire
16/07/2025

Intuitive demonstrates telesurgery capabilities

This landmark event involved Doug Stoddard, MD, located in Peachtree Corners, GA, and Andrea Pakula, MD, located remotely in Strasbourg, France. Together, using a dual console da Vinci 5 system, they performed a telesurgery procedure on an advanced tissue model developed by Intuitive to replicate the behavior of live tissue.During the demonstration, Stoddard, whose console was alongside the da Vinci 5 patient cart and tissue model, was able to pass control of surgical instruments back and...
Nasdaq GlobeNewswire
16/07/2025

Vivid Dx Appoints Diagnostics Veteran John Sperzel as Chief Executive Officer…

Sperzel has over three decades of executive leadership in the diagnostics sector. He previously served as Chairman and CEO of T2 Biosystems, President and CEO of both Chembio Diagnostics and Accriva Diagnostics (Werfen), and President of Axis-Shield (Alere). Earlier in his career, he held executive leadership roles at Bayer Diagnostics (Siemens), Werfen, and Boehringer Mannheim Diagnostics (Roche).A spin-out from the University of Oxford, Vivid Dx is developing a next-generation platform...
Nasdaq GlobeNewswire
16/07/2025

Rwazi Raises $12M to Replace Every Gut Call with an AI Copilot

"For decades, decisions have been driven by instinct. But gut calls are expensive — and in today's market, they're dangerous," said Joseph Rutakangwa, Co-Founder & CEO. "This raise lets us put a real-time AI copilot in the hands of every decision-maker — so teams can move faster, smarter, and with total clarity." "For decades, decisions have been driven by instinct. But gut calls are expensive — and in today's market, they're dangerous," said Joseph Rutakangwa…
PR Newswire
16/07/2025

Amphista Therapeutics announces achievement of a research milestone in its…

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025– Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery research milestone under its exclusive research collaboration and licence agreement with Merck. In conjunction with the milestone...
Nasdaq GlobeNewswire
16/07/2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Company Announcement Net sales of DARZALEX ®in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj , sold under the...
Nasdaq GlobeNewswire
16/07/2025

KFSHRC Receives Global Healthcare Accreditation for Medical Travel Services

This accreditation affirms our commitment to providing international patients with exceptional care," said Dr. Amaal AlDakheel, Director of International Healthcare Services at KFSHRC. "The GHA accreditation process was more than a compliance exercise — it was a valuable learning journey that offered opportunities for deep reflection, shared insights, and professional exchange with expert surveyors. It further strengthened KFSHRC's readiness to lead as premier destination for…
PR Newswire
16/07/2025

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by…

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen...
PR Newswire
16/07/2025

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and…

Under the leadership of new CEO Markus Granlund, TFS has embraced a decentralized structure that empowers each therapeutic area to own end-to-end delivery. In ophthalmology, that vision is led by Marcia Swank, Vice President and Head of Ophthalmology, who has shaped the unit into a focused partner for companies developing therapies and devices for eye conditions. Under the leadership ofnew CEOMarkus Granlund , TFS has embraced a decentralized structure that empowers each therapeutic area...
PR Newswire
16/07/2025

Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac…

The study presents the long-term follow-up of patients enrolled in the initial pilot trial of the Cardiac Microcurrent Implantable Device (C-MIC), designed to restore myocardial function in patients with chronic heart failure. This publication marks the first report of sustained clinical benefit following the discontinuation of active therapy—two years after initial device implantation. The study presents the long-term follow-up of patients enrolled in the initial pilot trial of the Cardiac...
PR Newswire
16/07/2025

Enhance your Meals and Support your Health with our Premium Canned Tomatoes…

A Trusted Partner for Your Kitchen and Health"Our mission is to provide British families and culinary creators with high-quality, nutritious ingredients they can trust," said Giovanni De Angelis, ANICAV General Director. "Our canned tomatoes not only add flavour to your meals but also deliver essential nutrients that support health and well-being. We believe that nutritious eating should be simple, accessible but at the same time delicious." A Trusted Partner for Your Kitchen…
PR Newswire
16/07/2025

Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

Outlook 2025 - Unchanged Outlook 2025 - Unchanged �� * The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta,and royalty on Sanofi's sales of Altuviiio and Beyfortus. Investors, analysts, and the media are invited to a conference call on the same day at14:00 CEST,13:00 GMT, and08:00 EST. The call will include a presentation of the results and a Q&A session. The presentation can be...
PR Newswire
16/07/2025

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for…

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degenerationDesignation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathwaysGeographic atrophy is an advanced form of dry age-related macular degeneration, that can lead to permanent vision lossParis, July 16, 2025. The US Food and Drug Administration (FDA) has granted fast track designation to SAR446597, a one-time...
Nasdaq GlobeNewswire
16/07/2025

Fujitsu and Acer Medical trial AI service that assesses future disease risk in…

Under the business model Fujitsu Uvance, Fujitsu is building an ecosystem of Uvance Partners that will apply data and AI towards the resolution of social issues. Through co-creation with these partners, and utilizing AI Decision Intelligence, Fujitsu aims to realize high-end health management services and advance people's wellbeing. Under the business model Fujitsu Uvance, Fujitsu is building an ecosystem of Uvance Partners that will apply data and AI towards the resolution of social issues...
PR Newswire
16/07/2025

ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO

RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing approximately 33 million cases of LRTIs, 3.6 million hospitalizations, and 101,400 deaths annually, with 97% of deaths occurring in low- and middle-income countries (LMICs). Despite the severe threat, current specific treatment options for RSV are extremely limited, and there is a clinical urgent need for safe, effective, and child-appropriate innovative drugs. The…
PR Newswire
16/07/2025

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

Each Unit will consist of one (1) post-consolidation common share in the capital of the Company (each, a "Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a "Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Each Unit will consist…
PR Newswire
16/07/2025

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in…

Key Takeaways from the Menin Inhibitors Market Report Key Takeaways from the Menin Inhibitors Market Report Discover which indication is expected to grab the major menin inhibitors market share @Menin Inhibitors Market Report Menin Inhibitors Market Dynamics The menin inhibitors market is emerging as a highly promising area within oncology, particularly in the treatment of hematological malignancies. The primary driver for this market is therising prevalence of acute...
PR Newswire
15/07/2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025

About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a…
PR Newswire
15/07/2025

The Board of Directors of Sobi exercises authorisation for repurchase of shares…

Today, the Board of Directors has resolved to, conditional upon subscription and payment by Svenska Handelsbanken AB, exercise the repurchase authorisation for the said purpose by repurchasing all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 16 July – 7 November 2025. Today, the Board of Directors has resolved to, conditional upon...
PR Newswire
15/07/2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – July 15, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 15, 2025, from Atlas Special…
Actusnews Wire
15/07/2025
Altri  Comunicati